

Radiation prior to combination-immunotherapy in patients with metastatic renal cell carcinoma (mRCC) and bone metastases

Abstract#N20



Hesham Yasin, Yu-Wei Chen, Matthew Tucker, Kathryn Eby Beckermann, Brian Rini Vanderbilt-Ingram Cancer Center, Nashville, TN

Patient Characterictiv

Background

- Retrospective studies and post-hoc analyses have shown that patients with metastatic renal cell carcinoma (mRCC) and bone metastasis have worse outcomes.
- A synergistic interaction between radiation (XRT) and Immunotherapy (IO) has been postulated.
- We performed a retrospective review of patients with bone metastasis treated with immunotherapy (IO)based combination therapy, with and without prior XRT.

Methods


- 28 patients with mRCC and bone metastasis treated with IO-based combinations at Vanderbilt-Ingram Cancer Center were identified.
- Data cutoff was August 31,2021.
- Patients who received XRT within six months of IO were included as having prior-XRT.
- Descriptive analyses were used to present patient baseline characteristics.
- Progression free survival (PFS)/Overall survival (OS), and objective response rate (ORR) were compared with Kaplan Meier and chi square statistics, respectively.

Patient Characteristics		
Prior XRT (n=12)	No prior XRT (n=16)	
56 (range 50-74)	57 (range 51-78)	
10/12 (83%)	13/16 (81%)	
1 Favorable 9 Intermediate 2 poor	2 Favorable 12 Intermediate 2 Poor	
5/12 (42%)	13/16 (81%)	
4/16 (25%)	3/12 (25%)	
	Prior XRT (n=12) 56 (range 50-74) 10/12 (83%) 1 Favorable 9 Intermediate 2 poor 5/12 (42%)	

Immunotherapy combinations patient received

Regimen Received	Prior XRT	No Prior XRT
ipilimumab/Nivolumab	9/12	8/16
Pembrolizumab/Axitinib	2/12	8/16
Avelumab/Axitinib	1/12	

Kaplan-Mier estimates for progression free survival



Results

- The ORR among patients in the no-XRT group was 19% (3/16) compared with 17% (2/12) in the prior-XRT group; odds ratio was 0.87 (0.12-6.21; p=0.89).
- The median PFS was 3.5 months (range, 1.5-11.0) in the no-XRT group and 2.8 mo (1.4-14.7) in the prior-XRT group; HR 1.05 (0.46-2.3; p=0.90.)
- The median OS was 18.8 mo (4.7-42.5) in the no-XRT group, and the mOS was not reached (7.4-NR) in the prior-XRT group [hazard ratio (HR) was 0.20 (0.03-1.62; p=0.13)]

Conclusions

Overall clinical outcomes were poor in this population of patients with mRCC to bone.

No major differences in clinical outcomes were observed in patients based on prior XRT.

Further studies are needed to evaluate the role of XRT prior to immunotherapy.

References

Mollica V. et al. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. *Curr Drug Targets*. 2020;21(14):1463-1475. doi:10.2174

Masini C et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study [published online ahead of print, 2021 Sep 30]. *Eur Urol*. 2021;S0302-2838(21)02040-6. doi:10.1016/j.eururo.2021.09.016

Hammers HJ et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). In: 2020 Genitourinary Cancers Symposium (2020).